University of Kansas

Silvergate Pharmaceuticals Inc.

Nps Pharmaceuticals, Inc.

Silvergate Pharmacauticals, Inc.

Aventis Pharmaceuticals Inc.

Hoechst Marion Roussel Deutschland Gmbh

Lian G Rajewski

John L Haslam

Roger A Rajewski

Kathleen Heppert

Michael C Beckloff

Robert Mauro

Peter Colabuono

Frank Segrave

Ian A Tomlinson

Edward D Daugs

James D Pipkin

Alexey L Margolin

Thomas B Marriott

Jonathan C Evans

Chi-Hsin Richard King

Paul F Skultety

Hans-Wolfram Flemming

James E Hitt

Thomas T Ortyl

Johannes Nicolaas Koek

Sandra K Stolz-Dunn

Gerard Guillamot

John R Lefler

Sharon K Minish

Frank Seagrave

David S Wells

Frederick M Laskovics

Alan G Bina

Robert A Hawthorne

Marvin J Sack

Thomas He Hilpert

Alonzo L Tigner

Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.

Enalapril compositions

The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.

Rapidly dissolving pharmaceutical compositions comprising pullulan

Sustained-release compositions for delivering therapeutic concentrations of isovaleramide, isovaleric acid, and certain structurally related compounds are provided for the treatment for a variety of pathological conditions, including epilepsy and spasticity, which are ameliorated by effecting a modulation of CNS activity. The ability of the compositions to sustain relatively constant levels of the drug at a therapeutic dose in the serum for extended periods of time enables a once or twice daily administration schedule.

Sustained-release formulations for treating CNS-mediated disorders

Growing community of inventors

Lawrence, KS, United States of America

Lian G Rajewski